Display options
Cite
Houston AR, Beall RF, Attaran A. Upstream solutions for price-gouging on critical generic medicines. J Pharm Policy Pract. 2016;9:15doi: 10.1186/s40545-016-0064-8.
Houston, A. R., Beall, R. F., & Attaran, A. (2016). Upstream solutions for price-gouging on critical generic medicines. Journal of pharmaceutical policy and practice, 915. https://doi.org/10.1186/s40545-016-0064-8
Houston, Adam R, et al. "Upstream solutions for price-gouging on critical generic medicines." Journal of pharmaceutical policy and practice vol. 9 (2016): 15. doi: https://doi.org/10.1186/s40545-016-0064-8
Houston AR, Beall RF, Attaran A. Upstream solutions for price-gouging on critical generic medicines. J Pharm Policy Pract. 2016 May 02;9:15. doi: 10.1186/s40545-016-0064-8. eCollection 2016. PMID: 27141308; PMCID: PMC4852412.
Copy Download .nbib Format: NLM
Share it on

J Pharm Policy Pract. 2016 May 02;9:15. doi: 10.1186/s40545-016-0064-8. eCollection 2016.

Upstream solutions for price-gouging on critical generic medicines.

Journal of pharmaceutical policy and practice

Adam R Houston, Reed F Beall, Amir Attaran

Affiliations

  1. University of Ottawa, Room 221 1 Stewart St, Ottawa, ON K1N 6N5 Canada.

PMID: 27141308 PMCID: PMC4852412 DOI: 10.1186/s40545-016-0064-8

Abstract

Exorbitant price increases for critical off-patent medicines have received considerable media attention in recent months, leading to an investigation by the U.S. Senate. However, much of this attention has focused upon the companies that initiated the price increases, all of whom had recently acquired the drugs in question. Overlooked are upstream interventions with the originators of these drugs to prevent generics trolling in the first place. Using the particular example of Eli Lilly and Company's efforts to divest itself of cycloserine, a flawed process that paved the way for the recent price hike by Rodelis Therapeutics, this article highlights the responsibilities of drug originators, and safeguards to ensure similar rights transfers do not affect ongoing affordable access.

Keywords: Cycloserine; Essential medicines; Generic drugs; Generics trolling; Pharmaceutical pricing; Pyrimethamine

References

  1. Science. 2001 Aug 10;293(5532):1049-51 - PubMed
  2. BMJ. 2015 Nov 09;351:h5989 - PubMed
  3. N Engl J Med. 2016 Feb 25;374(8):703-6 - PubMed

Publication Types